ISCT in the News

 2025    2024   2023

ISCT–JSRM 5-Year Joint Strategic Collaboration on Clinical iPSCs Launching Inaugural Joint Collaboration in Kobe, Japan - March 21, 2026
Mar 3, 2026

The International Society for Cell & Gene Therapy (ISCT), the translation-focused global community of cell and gene therapy experts and the Japanese Society for Regenerative Medicine (JSRM), advancing iPSC-based therapies, jointly announce a 5-year strategic partnership to advance iPSC-based therapies globally.

The ISCT–JSRM Joint Strategic Collaboration on Clinical iPSCs represents a landmark in the history of international regenerative medicine collaboration...

The Future of Cell and Gene Therapy: Navigating Innovation, Regulation, and Manufacturing Challenges
Aug 11, 2025

An interview with Philip Vanek, chief commercialization officer of the International Society for Cell & Gene Therapy (ISCT), reveals both promising developments and significant concerns shaping the advanced therapies sector’s trajectory through 2025 and beyond. This interview was conducted with support from Tozaro.

Gene editing leaders call for 10-year suspension of heritable human genome editing
May 28, 2025

An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), extending a moratorium that was first proposed in the fallout of a Chinese researcher’s widely decried use of CRISPR on human embryos.

Industry groups call for 10-year halt on heritable human genome editing
May 27, 2025

Three cell and gene therapy industry groups — the International Society for Cell & Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), and the American Society of Gene & Cell Therapy (ASGCT) — have released a joint statement calling for a 10-year international moratorium on heritable human genome editing (HHGE).

ISCT, ARM, and ASGCT Issue Unified Joint Statement Calling for 10-year Global Moratorium on Heritable Human Genome Editing
May 27, 2025

The International Society for Cell & Gene Therapy (ISCT), in partnership with the Alliance for Regenerative Medicine (ARM) and the American Society of Gene & Cell Therapy (ASGCT), today issued a unified joint statement calling for a 10-year global moratorium on heritable human genome editing (HHGE).  This action reflects significant concerns over the current lack of scientific evidence to ensure the safety of HHGE, the limited number of use cases amid rapidly advancing alternative therapies, and the absence of global ethical consensus. 

Scientific societies call for a moratorium on using CRISPR to create genetically modified children
May 13, 2025

ISCT, ASGCT, and ARM in process of publishing a joint position to offer guidance and to recommend a 10-year moratorium to countries deciding whether and/or how to regulate germline and other genome editing. 

Advocacy groups and experts call for decade-long ban on germline editing

May 13, 2025

Cell and gene therapy advocacy organizations are jointly calling for a 10-year international moratorium on gene editing of the human germline.

Preparing for the Future: What will ISCT 2025 Deliver? 

Apr 30, 2025

Phil Vanek, PhD, ISCT Chief Commercialization Officer, sits down with the RegMedNet team to discuss upcoming highlights from ISCT 2025 New Orleans

Advancing innovation and impact at ISCT 2025

Apr 25, 2025

Miguel Forte, MD, PhD, ISCT President, shares his insights on what sets ISCT 2025 apart from other sector events 

ISCT Announces Dr. Phil Vanek as next Chief Commercialization Officer

Jan 30, 2025

The International Society for Cell & Gene Therapy (ISCT) is delighted to announce the appointment of Phil Vanek, PhD, as ISCT Chief Commercialization Officer (CCO), effective January 1, 2025, through December 31, 2026.